SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following an earnings report that exceeded expectations, sparking optimism about the company's turnaround and future growth prospects in areas like AI. The community is focused on potential short squeezes, new partnerships, and the impact of government investments, while some are wary of overvaluation. Discussions also involve confidence in the CEO's strategy and broader sector dynamics.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai (BBAI) is trending as investors discuss the company's potential role in airport security and biometric identity solutions, particularly following news of its technology being deployed at Chicago O'Hare International Airport. Community members are debating the significance of this deployment, with some seeing it as a major catalyst and others wanting to see larger government contracts. Bullish sentiment revolves around BBAI's presence in national security and the potential for further expansion, while bears express concern over dilution and earnings.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending amid discussions around its Q3 earnings, production adjustments, and the broader EV market. Community sentiment is mixed, with some expressing concerns about lowered profit guidance and the impact of a supplier fire, while others highlight positive sales figures and potential tariff relief. Overall, the stock's movement is tied to both company-specific news and the evolving dynamics of the automotive industry.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor (DECK) is trending due to a mix of reactions to earnings, including a beat on estimates coupled with concerns about slowing growth and tariff impacts. The community is debating whether the stock's dip represents a buying opportunity or signals deeper issues with leadership and market sentiment in the retail apparel sector. Discussions also focus on the potential impact of share buybacks and shifting consumer trends in the outdoor and footwear markets.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending due to a lowered Q1 revenue outlook, attributed to customer upgrades delaying shipments, though the company reaffirmed its full-year guidance. Community discussions revolve around management's credibility and the impact on investor confidence, with some viewing the dip as a buying opportunity based on long-term AI growth potential. The broader context includes comparisons to competitors and debates over SMCI's execution in the booming AI server market.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont Corp ($NEM) is trending as investors discuss the implications of its recent earnings beat and potential future growth amid rising gold prices. Community members are weighing in on the impact of increased capital spending and debt reduction, as well as the company's exposure to gold's performance. There's also chatter about a potential acquisition and a shift in leadership.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending due to a cloud deal with Anthropic, giving the AI company access to Google's TPU chips and computing capacity. The community is discussing the potential impact of this deal on AI development and GOOGL's future. Some investors see this as a positive catalyst, while others are concerned about competition and market share.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies behind its vision of uniting the cannabis culture with crypto, envisioning it as a currency befitting our future world. Many allude to it being like Bitcoin but way higher. Community members highlight its organically cultivated community pushing for the peoples medicine and the plant that has the POTential to heal the earth and us.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Inhibrx Biosciences Inc.

Inhibrx Inc

Inhibrx is trending due to positive news regarding a potential accelerated approval pathway for its INBRX-101 drug, leading to a significant pre-market surge. The community is actively discussing the validity and impact of this news, with some expecting further gains while others anticipate a pullback. Analysts are weighing in, with raised price targets reflecting optimism about the drug's prospects in treating AATD.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its potential role in AI infrastructure, fueled by a $200M deal with Palantir and upcoming earnings. Community talking points include LUMN being undervalued like PLTR was years ago and its fiber optic network being essential for AI data centers. Some are drawing attention to LUMN's debt, while others suggest the company's strategic shift and AI-driven demand could lead to significant growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of Shareholders

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of...

NVS Reports Positive Late-Stage Data on Kidney Disease Drug 

Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline 

Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.

Shares of Tourmaline Bio (TRML) jumped 58% in the pre-market session on Tuesday after Novartis (NVS) announced that it has agreed to acquire the smaller biopharmaceutical firm.Under the <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-acquire-tourmaline-bio-complementing-cardiovascular-pipeline-pacibekitug-treatment-atherosclerotic-cardiovascular-disease-ascvd">deal</a>, Novartis will commence a tender offer to purchase all outstanding shares of Tourmaline common stock through an indirect wholly owned unit. The deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price and values the company at about $1.4 billion on a fully diluted basis. Following the closing of the tender offer, the unit will merge with Tourmaline, and the company will become an indirect wholly owned subsidiary of Novartis.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TRML">TRML stock</a> jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/NVS">NVS stock</a> fell from ‘Neutral’ to ‘Bearish territory, while message volume rose from ‘low’ to ‘normal’ levels.Novartis stated that the acquisition includes Tourmaline’s Pacibekitug being developed as a treatment option for atherosclerotic cardiovascular disease or the build-up of fats, cholesterol, and other substances in and on the artery walls. Pacibekitug complements Novartis’ cardiovascular strategy, the company said, while noting that with mid-stage trials of Pacibekitug already well-advanced, the company will acquire a late-stage-ready asset."Inflammation is a major driver of cardiovascular disease, and the team at Tourmaline has made significant progress with this asset. We are excited to bring Pacibekitug into the Novartis portfolio and collaborate with the Tourmaline team to advance its development as we diversify our efforts in cardiovascular care," said Shreeram Aradhye, Chief Medical Officer of Novartis. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; The transaction has been unanimously approved by the Board of Directors of both companies. It is expected to close in the fourth quarter of 2025, subject to the satisfaction or waiver of customary closing conditions. Until the transaction is closed, the two companies will continue to operate as separate, independent entities, Novartis said.TRML stock is up by 49% this year, while NVS stock gained over 32%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-launches-ai-machine-learning-platform-called-tunelab/chwKTzARdsU">Eli Lilly Launches AI, Machine Learning Platform Called TuneLab For Biotech Companies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened

Novartis has announced that it has agreed to acquire the biopharmaceutical firm, and the deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price. 

Equity

Novartis has announced that it has agreed to acquire the biopharmaceutical firm, and the deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price. 


Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's  What You Should Know

The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Tourmaline Bio (TRML) Receives a Buy from Piper Sandler

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Tourmaline Bio (TRML Research Report), with a price targ...

The Lustgarten Foundation Appoints Two New Board Members

The Lustgarten Foundation Appoints Two New Board Members The Lustgarten Foundation Appoints Two New Board Members PR Newswire WOODBURY, N.Y., June 13, 2024 Richard Barakat, MD, and Aaron Kantoff join...

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of...

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $55.60 Consensus Target Price from Analysts

Shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have earned an average recommendation of "Buy" from the six analysts that are currently covering the firm, Marketbeat reports. Six...

Tourmaline Bio (NASDAQ:TRML) Price Target Increased to $72.00 by Analysts at Jefferies Financial Group

Tourmaline Bio (NASDAQ:TRML  Free Report) had its target price raised by Jefferies Financial Group from $41.00 to $72.00 in a report released on Wednesday morning, Benzinga reports. Jefferies...

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.

Current Price	$47.96
Prev Close	$47.97
Open	$47.96
Dividend Yield	0.00%
50-Day Moving Average	$39.15
Beta	0.97
Avg. Volume	2.02M
PE Ratio	-13.96

52-Week High	$48.27
52-Week Low	$11.56
Market Capitalization	$1.23B
EPS (Annual)	-$2.89
Price to Book	4.75
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

TRML
Tourmaline Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TRML News

TRMLTourmaline Bio Inc